Compare PHAR & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAR | NXP |
|---|---|---|
| Founded | 1988 | N/A |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 898.0M |
| IPO Year | 2020 | 1995 |
| Metric | PHAR | NXP |
|---|---|---|
| Price | $11.57 | $14.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $38.33 | N/A |
| AVG Volume (30 Days) | 18.0K | ★ 142.3K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.04 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.62 | $13.89 |
| 52 Week High | $21.34 | $14.65 |
| Indicator | PHAR | NXP |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 44.34 |
| Support Level | $9.62 | $13.94 |
| Resistance Level | $17.89 | $14.51 |
| Average True Range (ATR) | 0.67 | 0.10 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 58.51 | 28.01 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund has single operating segment.